$1.23
-0.11 (-8.21%)
Open$1.42
Previous Close$1.34
Day High$1.42
Day Low$1.21
52W High$8.08
52W Low$1.17
Volume—
Avg Volume699.6K
Market Cap33.36M
P/E Ratio—
EPS$-10.41
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,685.4% upside
Current
$1.23
$1.23
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.12M | 6.05M | 5.52M |
| Net Income | -607,977,939 | -605,390 | -589,967 |
| Profit Margin | -2,630.1% | -10.0% | -10.7% |
| EBITDA | -477,034,016 | -1,010,044 | -924,468 |
| Free Cash Flow | — | -597,812 | -774,673 |
| Rev Growth | — | +6.5% | -1.7% |
| Debt/Equity | 1.21 | 0.26 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |